All News
SGLT-2 inhibitors for the prevention of autoimmune rheumatic diseases
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have been shown to have effects beyond glycemic control, showing cardioprotective and nephroprotective benefits along with modest weight loss.
Read Article
FDA Approves Obinutuzumab for Active Lupus Nephritis
The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis.
Read Article
Telitacicept Effective in Systemic Lupus Erythematosus
The NEJM has published a report from van Vollenhoven et al showing a new dual B cell inhibitor, telitacicept, to be effective when given to active systemic lupus erythematosus (SLE) patients; but this comes with a few https://t.co/lwq8ZUMTQ8
Dr. John Cush RheumNow ( View Tweet)
SAIL-RA: Finding ILD in Early RA
Cohort study of early rheumatoid arthritis (RA) patients finds that interstitial lung disease (ILD) begins early in the course of RA, with certain factors enhancing this risk.
https://t.co/nI0YuYd3YS https://t.co/YR3Gg1kr59
Dr. John Cush RheumNow ( View Tweet)
FDA has approved Genentech’s CD20-targeting antibody obinutuzumab (Gazyva) for the treatment of adult patients with lupus nephritis who are receiving standard therapy. https://t.co/0eGwGnSDYf https://t.co/Z6w2iP4u3e
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 423 seropositiv RA pts (SPRA) finds 21% with baseline ILD; over 10 yrs 31% had ILD. High monocyte counts signif higher in RA-ILD; whereas RF, CCP did not predict. Age & ILD predicted mortality - not monocytes, RF or CCP https://t.co/8H4wqZI3WQ https://t.co/dK9iHwj3cz
Links:
Dr. John Cush RheumNow ( View Tweet)
Interleukin-18 (IL-18) regulates appetite, body weight & glucose homeostasis. IL-18 deficiency may lead to obesity, but chronic IL-18 signalling promotes liver fibrosis. IL-18 is Elevated in obesity and diabetes mellitus https://t.co/Xylvexqvtg https://t.co/sRutSCoLf9
Dr. John Cush RheumNow ( View Tweet)
Study of biopsy proven lupus nephritis pts (1970-2024) - a total of 324 LN pts followed for median 9.9 yrs -- 30 (9.3%) developed Venous Thromboembolic event (VTE); time from LN to 1st VTE 4.4 yrs. Predictors were SLEDAI-2K score (HR= 1.05) and proteinuria level (HR 1.26)
Dr. John Cush RheumNow ( View Tweet)
From the plenary to posters, RheumNow is your companion for ACR Convergence 2025. Expect:
• KOL videos
• Clinical trial highlights
• Daily faculty recaps
• Live streaming
#ACR25 #Rheumatology #ClinicalTrials https://t.co/zZAwYINmC2
Dr. John Cush RheumNow ( View Tweet)
“Never in the field of human conflict was so much owed by so many to so few.” –
Winston Churchill https://t.co/ZAcYBpOmjy
Dr. John Cush RheumNow ( View Tweet)
Review of IL-1 family cytokines in inflammation and immunity - including, IL-1, IL-18, IL-33, IL-36, IL-37, IL-38, IL-1Ra, etc. Full read -- Good Reference!! https://t.co/m2CwDydnB0 https://t.co/h90bdzv3y7
Dr. John Cush RheumNow ( View Tweet)
Mediterranean Diet Efficacy in Psoriasis
A small clinical trial found that a 16-week Mediterranean diet reduced psoriasis severity, presumably due to anti-inflammatory benefits of extra virgin olive oil, plant-based foods, and moderate meat consumption, according to a study https://t.co/fiJTx6TEZq
Dr. John Cush RheumNow ( View Tweet)
Whole Body MRI for Arthritis
Whole-body MRI (wbMRI) reviews have increasingly appeared in the medical literature, owing to better scanners, faster imaging times and reduced costs. Use of such non-oncologic musculoskeletal imaging provides high-contrast resolution images of the https://t.co/RQBPDhf1Vb
Dr. John Cush RheumNow ( View Tweet)
Fibromyalgia in PsO & PsA is linked to greater treatment complexity and shorter biologic therapy survival. Retro matched 1:4 cohort study 61K PsO& 244K controls. FM prevalence 3.3% (OR 1.45). In PsA decr biologic survival (6 vs 10yrs) w/ incr switching (HR 1.82)
Dr. John Cush RheumNow ( View Tweet)
Skin Biopsies to Predict Scleroderma Outcomes?
Researchers from the Hospital for Special Surgery and Weill Cornell Medicine have shown that skin biopsies in patients with systemic sclerosis (SSc) can define a fibroblast immunophenotype that may have prognostic and early https://t.co/z3LykOgyHO
Dr. John Cush RheumNow ( View Tweet)
CONGRATULATIONS: Dr. Lauren Henderson has been awarded the Gale & Ira Drukier Prize in Children’s Health Research. Lauren is a pediatric rheum at Boston Children’s Hospital, focused in difficult JIA. She has studied T-B cells interactions & long-term joint damage in JIA https://t.co/uYWrh0oasy
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of whole-body cryotherapy (WBC) in Ankylosing spondylitis (AS) - 5 studies & 310 #AS pts. Temps (−60°C to −10°C) & duration (80 sec to 3 min) varied. WBC significantly mproved BASDAI (p<0.001), ASDAS ( 0.015), BASFI (0.006), & VAS pain (.005), but NOT CRP https://t.co/6Sj3bg096X
Dr. John Cush RheumNow ( View Tweet)
A high ANA titer (≥1:640) in individuals without an autoimmune disease was found to be strongly associated with liver-related disorders, including nonalcoholic and alcoholic liver disease
Arthritis Care & Research
https://t.co/tkMpPFPnhc https://t.co/Bk9JXWTsOU
Links:
ACR_Journals ACR_Journals ( View Tweet)
JAMA Pediatrics study of 1,473 young US adult, finds 1/4 use cannabis or alcohol for sleep (18% cannabis; 7% EtOH), even though these may interfere with quality or ability to stay asleep. In those using cannabis in the last yr, 41 reported using cannabis to sleep. https://t.co/fdW6bdDM3I
Dr. John Cush RheumNow ( View Tweet)
Arthritis Pain and Education Gaps Linked Save
New research from The University of Texas at Arlington shows that differences in state welfare policies are linked to rising arthritis-related joint pain across much of the U.S.
https://t.co/cGRH9X6pMZ https://t.co/J1SDeKrytn
Dr. John Cush RheumNow ( View Tweet)
